FiercePharmaAsia—Eli Lilly rushes to FDA with its COVID-19 antibody for emergency green light, reveals new cocktail therapy data

Eli Lilly is seeking FDA emergency use authorization of its COVID-19 antibody cocktail upon an interim analysis of the phase 2 Blaze-1 trial, which showed the combo reduced viral load, symptoms, and the rate of hospitalization and ER visits. The therapy combines LY-CoV555, from a collaboration with AbCellera, and LY-CoV016, which Lilly licenses from China’s Junshi Biosciences.